- JES5-16E3 (See other available formats)
- Regulatory Status
- Other Names
- Interleukin-10, Cytokine synthesis inhibitory factor (CSIF), B cell derived T cell growth factor (B-TCGF)
- Rat IgG2b, κ
- Ave. Rating
- Submit a Review
- Product Citations
IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. IL-10 inhibits IFN-γ, TNF-β, and IL-2 production by Th1 clones; inhibits macrophage-mediated IL-1, IL-6, and TNF-α synthesis; suppresses the delayed type hypersensitivity response; stimulates Th2 cell response (which results in elevated antibody production); and promotes mast cell proliferation in combination with IL-4.Product Details
- Antibody Type
- Host Species
- E. coli-expressed, recombinant mouse IL-10
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
µg sizes: 0.2 mg/ml
µl sizes: lot-specific (please contact technical support for concentration and total µg amount)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
ICFC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet™.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
- Excitation Laser
Violet Laser (405 nm)
- Application Notes
ELISA or ELISPOT Detection1,9,11: The biotinylated JES5-16E3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES5-2A5 antibody (Cat. Nos. 504902 & 504904) as the capture antibody.
ELISA Capture: The purified JES5-16E3 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated JES5-2A5 antibody (Cat. No. 505003) as the detection antibody and recombinant mouse IL-10 (Cat. No. 575809) as the standard.
Neutralization14: The Ultra-LEAF™ purified JES5-16E3 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Flow Cytometry3: The fluorochrome-labeled JES5-16E3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-10-producing cells within mixed cell populations.
Additional reported applications (for relevant formats) include: immunohistochemistry3.
(PubMed link indicates BioLegend citation)
- Simkin G, et al. 2000. J. Immunol. 164:2457.
- Kitagaki K, et al. 2002. Clin. Diagn. Lab Immunol. 9:1260.
- Khanna A, et al. 2000. J. Immunol. 164:1346.
- Sander B, et al. 1993. J. Immunol. Methods 166:201.
- Litton M, et al. 1994. J. Immunol. Methods 175:47.
- Andersson U, et al. 1999. Detection and qunatification of gene expression. New York:Springer-Verlag.
- Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
- Wang W, et al. 2004. FASEB J. 18:1043.
- Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
- Lawson BR, et al. 2007. J. Immunol. 178:5366.
- Xu G, et al. 2007. J. Immunol. 179:5358. PubMed
- Brummel R, et al. 2005. J. Immunol.174:2429. PubMed
- Kang YJ, et al. 2007. Stem Cells 25:1814. PubMed
- Seo N, et al. 2001. Immunology. 103:449. (Neut)
- Product Citations
AB_10900417 (BioLegend Cat. No. 505021)
AB_2563240 (BioLegend Cat. No. 505022)
- Acid-labile cytokine, dimer, 17-21 kD (Mammalian)
- Cell Sources
- Activated CD8+ T cells, Th0, Th2 subset of CD4+ T cells, Ly-1+ B cells, monocytes, macrophages, keratinocytes
- Cell Targets
- T cells, B cells, mast cells, macrophages
- IL-10R (CDw210)
- Cell Type
- Biology Area
- Molecular Family
- Antigen References
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. de Waal-Malefy R, et al. 1992. Curr. Opin. Immunol. 4:314.
3. Howard M, et al. 1992. Immunol. Today 13:198.
4. Quesniaux V. 1992. Res. Immunol. 143:385.
5. Norton SK, et al. 2008. J. Immunol. 180:2848.
- Downregulated by IL-4, IL-10
- Gene ID
- 16153 View all products for this Gene ID
- View information about IL-10 on UniProt.org
- What is the F/P ratio range of our BV421™ format antibody reagents?
It is lot-specific. On average it ranges between 2-4.
Customers Also Purchased
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.